TCTR20240404003Enrolling By Invitation1 期
Body composition change in people living with HIV after transition antiretroviral therapy from TDF/FTC/EFV to TDF/3TC/DTG. A randomized control trial
Ramathibodi Hospital foundation0 个研究点目标入组 170 人开始时间: 2024年4月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Patient living with HIV who can come follow up at Ramathibodi Hospital
- •2. Prescribed TDF/FTC/EFV at least 6 mo. prior include in this study
- •3. Age > 20 yr
- •4. HIV viral load <200 copies/mL
- •5. CD4 level > 200 cells/mL
- •6. Accept to join the project by signing the consent
排除标准
- •1. Follow up less than 2 times after join the project
- •2. Got pregnant during join the project
- •3. Got infected by opportunistic infection during join the project
- •4. Not viable for measured body composition using bioelectrical impedance analysis machine
研究者
相似试验
已完成
不适用
Metabolism and Body Shape of Healthy Children and Children With Chronic InfectionsHealthyLipodystrophyHyperlipidemiaHIV InfectionsNCT00001142Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)185
已完成
4 期
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected IndividualsHivHIV CardiomyopathyWeight Change, BodyHIV LipodystrophyCardiovascular DiseasesHIV InfectionsNCT04904406Thomas Benfield81
已完成
不适用
Changes in lipid profile in people living with HIV on stable protease inhibitors (PIs)-based regimens as second-line ART regimens switch to dolutegravir (DTG)-based regimenspeople living with HIVlipid profile, protease inhibitors, second-line ART regimens, switching, dolutegravirTCTR20240717004Faculty of Medicine, Chulalongkorn University144
终止
不适用
Body Composition, Bone Health and Hormonal Status in HIV-1-infected IndividualsHIV-1Treatment-naïveNCT03708289Universitair Ziekenhuis Brussel120
招募中
4 期
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA 001)HIVMetabolic abnormalityLipodystrophyInfection - Acquired immune deficiency syndrome (AIDS / HIV)Cardiovascular - Other cardiovascular diseasesCardiovascular diseaseACTRN12605000662662The University of New South Wales80